Sebi warns Dabur India over delay in disclosing USFDA warning letter
The market regulator has cautioned Dabur India over delayed disclosure of a USFDA warning letter, saying repeated violations could attract enforcement action under Sebi rules.
Attributed summary
The market regulator has cautioned Dabur India over delayed disclosure of a USFDA warning letter, saying repeated violations could attract enforcement action under Sebi rules.
Read the original report — Business Standard
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
